Physician profile
Theofanis Mitsinikos
NPI 1467624064
$156,730.56
in general payments reported to CMS, 2019-2025
63 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $15K · 2021: $13K · 2022: $13K · 2023: $27K · 2024: $26K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $20K · Consulting Fee: $16K · Honoraria: $13K · Travel and Lodging: $1,519 · Education: $88.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,400.00 |
| Food and Beverage | $19,968.05 |
| Consulting Fee | $15,920.75 |
| Honoraria | $13,000.00 |
| Travel and Lodging | $1,519.34 |
| Education | $88.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $34,036.55 | 2019-2024 | Farxiga, Lokelma |
| Mannkind Corporation | $23,965.93 | 2021-2025 | Afrezza, V-Go |
| Abbvie INC. | $22,207.60 | 2019-2025 | |
| Intra-Sana Laboratories | $14,444.33 | 2024-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Sanofi-Aventis U.S. LLC | $12,626.25 | 2019-2025 | |
| Amarin Pharma, INC. | $12,542.61 | 2019-2023 | |
| Intuity Medical INC | $6,993.58 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lilly USA, LLC | $6,681.01 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $3,010.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Ibsa Pharma INC. | $2,481.03 | 2022-2025 | Tirosint, Licart, Tirosint |
| Janssen Pharmaceuticals, INC | $2,471.50 | 2019-2021 | |
| Amgen INC. | $1,774.21 | 2019-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,682.74 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Xeris Pharmaceuticals, INC. | $1,217.17 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Horizon Therapeutics Plc | $974.02 | 2019-2023 | Tepezza |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $754.63 | 2021-2025 | |
| Medtronic, INC. | $692.18 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Dexcom, INC. | $680.89 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Corcept Therapeutics | $608.65 | 2019-2025 | Korlym |
| Vivus LLC | $582.87 | 2019-2025 | Qsymia, Pancreaze |
| Cvrx, INC. | $568.68 | 2023-2024 | Barostim Neo System |
| Amneal Pharmaceuticals LLC | $552.77 | 2019-2025 | Unithroid |
| Abbott Laboratories | $529.83 | 2019-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $462.86 | 2024-2025 | Yorvipath |
| Insulet Corporation | $395.86 | 2019-2024 | Omnipod |
| Ipsen Biopharmaceuticals, INC | $291.87 | 2019-2024 | Iqirvo |
| Novartis Pharmaceuticals Corporation | $288.19 | 2022-2025 | |
| Medtronic Minimed, INC. | $277.64 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $265.84 | 2019-2023 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $224.86 | 2019-2023 | |
| Radius Health, INC. | $213.63 | 2019-2025 | Tymlos |
| Esperion Therapeutics, INC. | $187.80 | 2020-2025 | Nexletol |
| Recordati_rare_diseases_inc. | $170.35 | 2025 | Isturisa |
| Kowa Pharmaceuticals America, INC. | $148.31 | 2021-2024 | Livalo |
| Pfizer INC. | $125.24 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $118.87 | 2020-2023 | Nexletol, Contrave, Nexlizet |
| Lifescan, INC. | $113.43 | 2020-2022 | |
| Antares Pharma, INC. | $113.31 | 2019-2024 | Tlando, Xyosted |
| Alexion Pharmaceuticals, INC. | $112.96 | 2022-2025 | Strensiq |
| Eisai INC. | $102.86 | 2019 | |
| Aytu Biopharma, INC. | $101.22 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $100.12 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Verity Pharmaceuticals INC. | $98.68 | 2024-2025 | Tlando |
| Madrigal Pharmaceuticals | $84.66 | 2025 | Rezdiffra |
| Clarus Therapeutics INC. | $82.31 | 2021 | |
| Shire North American Group INC | $74.94 | 2019 | |
| Ascensia Diabetes Care US INC. | $62.68 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $55.85 | 2019-2023 | Crysvita |
| Becton, Dickinson and Company | $44.13 | 2019 | |
| Endo USA, INC. | $41.69 | 2024-2025 | Aveed |
| Glaxosmithkline, LLC. | $39.44 | 2025 | Shingrix, Arexvy |
| Cequr Corporation | $38.67 | 2023-2024 | Cequr Simplicity |
| Amryt Pharma Holdings Ltd | $36.44 | 2022 | |
| Nevro Corp. | $34.68 | 2022-2023 | Senza |
| Zealand Pharma US, INC. | $19.69 | 2021 | |
| Almatica Pharma LLC | $18.71 | 2025 | Teriparatide |
| Nalpropion Pharmaceuticals LLC | $18.35 | 2019 | |
| Astellas Pharma US INC | $16.76 | 2025 | Veozah |
| Chiesi USA, INC. | $15.49 | 2024 | Mycapssa |
| Kyowa Kirin, INC. | $14.46 | 2024 | Crysvita |
| Regeneron Healthcare Solutions, INC. | $13.87 | 2019 | |
| Covidien Lp | $12.53 | 2019 | |
| Companion Medical, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theofanis Mitsinikos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.